ESMO 2019 | OpACIN and OpACIN-neo trial updates

Christian Blank

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, provides an update on the OpACIN (NCT02437279) and OpACIN-neo (NCT02977052) trials, with 3 year and 1.5 year updates respectively. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video